Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Genky DrugStares, 8% Increase in Ordinary Profit, Update Record High for Fourth Consecutive Term
9267 Genky DrugStores Co.,Ltd. 【J-GAAP】
Earnings ReportGenky DrugStares Co.,Ltd. <9267> [TSE Prime] announced its financial results after the market closed on July 29th (15:30). The consolidated ordinary profit for the fiscal year ended June 2025 increased by 6.8% from the previous period to 9.89 billion yen. For the fiscal year ending June 2026, the consolidated ordinary profit is expected to grow by 8.1% to 10.7 billion yen, marking the fourth consecutive term of record-high profits. This will be the thirteenth consecutive term of revenue and the fourth consecutive term of profit growth.
In the most recent three-month period, from April to June (4Q), the consolidated ordinary profit grew 10.6% from the same period last year, reaching 2.85 billion yen. The operating profit margin remained almost flat, changing from 5.2% in the same period last year to 5.3%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jun, 2023 | 169,059 | 6,709 | 7,079 | 4,764 | 156.9 | 12.50 | Jul 24, 2023 | J-GAAP |
| Jun, 2024 | 184,860 | 9,015 | 9,268 | 6,324 | 208.2 | 12.75 | Jul 29, 2024 | J-GAAP |
| Jun, 2025 | 200,786 | 9,658 | 9,899 | 7,066 | 232.5 | 13 | Jul 29, 2025 | J-GAAP |
| YoY | +8.6% | +7.1% | +6.8% | +11.7% | +11.7% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jun, 2025 Guidance | 202,000 | 10,000 | 10,220 | 7,000 | 230.3 | 13 | Jul 29, 2024 | J-GAAP |
| Jun, 2025 Results | 200,786 | 9,658 | 9,899 | 7,066 | 232.5 | 13 | Jul 29, 2025 | J-GAAP |
| Revision Rate | -0.6% | -3.4% | -3.1% | +0.9% | +1.0% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Dec, 2024 | 98,758 | 4,596 | 4,722 | 3,268 | 107.6 | 6.50 | Jan 27, 2025 | J-GAAP |
| Jul - Dec, 2025 Guidance | 109,210 | 5,270 | 5,360 | 3,700 | 121.4 | 6.50 | Jul 29, 2025 | J-GAAP |
| YoY | +10.6% | +14.7% | +13.5% | +13.2% | +12.9% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jun, 2024 | 184,860 | 9,015 | 9,268 | 6,324 | 208.2 | 12.75 | Jul 29, 2024 | J-GAAP |
| Jun, 2025 | 200,786 | 9,658 | 9,899 | 7,066 | 232.5 | 13 | Jul 29, 2025 | J-GAAP |
| Jun, 2026 Guidance | 221,840 | 10,500 | 10,700 | 7,500 | 246.1 | 13 | Jul 29, 2025 | J-GAAP |
| YoY | +10.5% | +8.7% | +8.1% | +6.1% | +5.8% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Jun, 2024 | 48,273 | 2,521 | 2,580 | 1,868 | 61.5 | 5.2 | Jul 29, 2024 | J-GAAP |
| Jul - Sep, 2024 | 50,050 | 2,272 | 2,300 | 1,584 | 52.1 | 4.5 | Oct 28, 2024 | J-GAAP |
| Oct - Dec, 2024 | 48,708 | 2,324 | 2,422 | 1,684 | 55.4 | 4.8 | Jan 27, 2025 | J-GAAP |
| Jan - Mar, 2025 | 48,625 | 2,243 | 2,324 | 1,605 | 52.8 | 4.6 | Apr 28, 2025 | J-GAAP |
| Apr - Jun, 2025 | 53,403 | 2,819 | 2,853 | 2,193 | 72.2 | 5.3 | Jul 29, 2025 | J-GAAP |
| YoY | +10.6% | +11.8% | +10.6% | +17.4% | +17.3% |
Related Articles
SCSK, Apr-Jun (1Q) Net Income Increases by 45%
Entrust, Apr-Jun (1Q) Ordinary Profit Increases by 22%
NIPPON GAS, Ordinary Profit Forecast for First Half Revised Upward by 24%
KOMORI, Apr-Jun (1Q) Ordinary Profit Decreases by 44%
KISSEI PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward to a Loss
JFE Systems, Apr-Jun (1Q) Ordinary Profit Increases by 24%
Central Japan Railway, Apr-Jun (1Q) Ordinary Profit Increases by 21%
NEC, Apr-Jun (1Q) Net Income Turns to Profit
Chubu Electric Power, Apr-Jun (1Q) Ordinary Profit Decreases by 16%
NIPPON CHUZO, Apr-Jun (1Q) Ordinary Profit Turns to Profit